Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04592666 2020-10-19

APPEAL

Phase 2 Unknown

226 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04500704 2020-08-05

ACROSS1

Phase 3 Unknown

166 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

Phase 3 Unknown

460 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04470076 2020-07-14

Neoafa

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

Phase 2 Unknown

168 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04015778 2020-02-12

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Phase 2 Unknown

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04108013 2019-09-27

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Phase 2 Unknown

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04054531 2019-09-10

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03062800 2019-06-05

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Phase 2 Unknown

232 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03647956 2019-04-17

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03413358 2018-01-29

Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid

Phase NA Unknown

240 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02734524 2018-01-23

A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Phase 2 Unknown

104 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03262948 2017-11-13

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer

Phase 3 Unknown

388 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03195569 2017-06-22

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Unknown

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01980472 2017-02-27

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02568033 2017-01-31

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Phase EARLY_PHASE1 Unknown

22 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

TRUMP

FTANLCNDG

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

neoSCORE

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.

NEOSUN

DYNAPET

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

F&C

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

EPIC

APPEAL

ACROSS1

ACROSS2

Neoafa

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

ANSWER

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid

A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer